Withdrawal from paroxetine can be severe, warns FDA -- Tonks 324 (7332): 260 -- BMJ
Alison Tonks, Bristol The first 150 words of the full text of this article appear below.
http://www.bmj.com/cgi/content/extract/324/7332/260
GlaxoSmithKline, a leading drugs manufacturer, was last week forced to admit that paroxetine, a widely prescribed antidepressant and the company's best selling drug, can cause severe withdrawal symptoms when stopped.
The Food and Drug Administration in the United States published a new product warning about the drug, and in the same week the International Federation of Pharmaceutical Manufacturers Associations declared the company guilty of misleading the public about paroxetine on US television a year ago.
"This drug has been promoted for years as safe and easy to discontinue," said Charles Medawar, head of Social Audit, a consumer research group specialising in medicines policy. "The fact that it can cause intolerable withdrawal symptoms of the kind that could lead to dependence is enormously important to patients, doctors, investors, and the company.
"GlaxoSmithKline has evaded the issue since
Sunday, 29 November 2009
SEROXAT SUFFERERS - STAND UP AND BE COUNTED: *** Exclusive - what it was really like for Fiddaman during cold turkey from Seroxat - here we bring you day 8
SEROXAT SUFFERERS - STAND UP AND BE COUNTED: Day 8 and Fiddaman is clearly finding it a laugh !!
SEROXAT SUFFERERS - STAND UP AND BE COUNTED: Day 8 and Fiddaman is clearly finding it a laugh !!: "Day 8 and Fiddaman is clearly finding it a laugh !!
click on link below to personally verify this Bob Fiddaman Blogspot Exclusive ***"
click on link below to personally verify this Bob Fiddaman Blogspot Exclusive ***"
Wednesday, 11 November 2009
Tuesday, 10 November 2009
He said J Bryce is a GSK quisling - we say Mark Harvey of Hugh James is a liar
Wednesday, 14 October 2009
GSK to appeal Kilker case - statement
GSK Statement on Jury Verdict in Paxil Product Liability Trial in Philadelphia Court of Common Pleas
http://bobfiddaman.blogspot.com/2009/10/gsk-to-appeal-kilker-case-statement.html
On October 13, 2009, a jury in the Philadelphia Court of Common Pleas returned a verdict against GlaxoSmithKline in a case alleging that Lyam Kilker was born with a rare heart defect as a result of his mothers use of Paxil during pregnancy.
GlaxoSmithKline disagrees with the verdict and will appeal. While we sympathize with Lyam Kilker and his family, the scientific evidence does not establish that exposure to Paxil during pregnancy caused his condition. Very unfortunately, birth defects occur in three to five percent of all live births, whether or not the mother was taking medication during pregnancy.
GlaxoSmithKline acted properly and responsibly in conducting its clinical trial program for Paxil, including sharing documentation and submitting results from studies on Paxil to regulators. Once approved for use, the company acted properly in marketing the medicine, including monitoring its safety, updating pregnancy information in the medicines labeling as new information became available, and in communicating important safety information to regulatory agencies, the scientific community and the public.
US Media enquiries:
Nancy Pekarek
(919) 483 2839
Mary Anne Rhyn
(919) 483 2839
Kevin Colgan
(919) 483 2839
Sarah Alspach
(919) 483 2839
http://bobfiddaman.blogspot.com/2009/10/gsk-to-appeal-kilker-case-statement.html
On October 13, 2009, a jury in the Philadelphia Court of Common Pleas returned a verdict against GlaxoSmithKline in a case alleging that Lyam Kilker was born with a rare heart defect as a result of his mothers use of Paxil during pregnancy.
GlaxoSmithKline disagrees with the verdict and will appeal. While we sympathize with Lyam Kilker and his family, the scientific evidence does not establish that exposure to Paxil during pregnancy caused his condition. Very unfortunately, birth defects occur in three to five percent of all live births, whether or not the mother was taking medication during pregnancy.
GlaxoSmithKline acted properly and responsibly in conducting its clinical trial program for Paxil, including sharing documentation and submitting results from studies on Paxil to regulators. Once approved for use, the company acted properly in marketing the medicine, including monitoring its safety, updating pregnancy information in the medicines labeling as new information became available, and in communicating important safety information to regulatory agencies, the scientific community and the public.
US Media enquiries:
Nancy Pekarek
(919) 483 2839
Mary Anne Rhyn
(919) 483 2839
Kevin Colgan
(919) 483 2839
Sarah Alspach
(919) 483 2839
Tuesday, 13 October 2009
Paxil Seroxat (birth defect) trial due to start today - "settled out of court last week"
Paxil Seroxat (birth defect) trial due to start today - "settled out of court last week"
Paxil (birth defect) trial due to start today - "settled out of court last week"
http://bobfiddaman.blogspot.com/2009/10/paxil-seroxat-birth-defect-trial-due-to.html
http://www.network54.com/Forum/281849/message/1255423909/Paxil+%28birth+defect%29+trial+due+to+start+today+-+%26quot%3Bsettled+out+of+court+last+week%26quot%3B
--------------------------------------------------------------------------------
A second Paxil case, expected to begin next Tuesday, was settled out of court last weekend. The next is not scheduled to begin in mid-November.
source - full report read on -
http://thestar.blogs.com/ethics/2009/10/first-paxil-trial-goes-to-the-jury.html
date - October 09, 2009
Paxil (birth defect) trial due to start today - "settled out of court last week"
http://bobfiddaman.blogspot.com/2009/10/paxil-seroxat-birth-defect-trial-due-to.html
http://www.network54.com/Forum/281849/message/1255423909/Paxil+%28birth+defect%29+trial+due+to+start+today+-+%26quot%3Bsettled+out+of+court+last+week%26quot%3B
--------------------------------------------------------------------------------
A second Paxil case, expected to begin next Tuesday, was settled out of court last weekend. The next is not scheduled to begin in mid-November.
source - full report read on -
http://thestar.blogs.com/ethics/2009/10/first-paxil-trial-goes-to-the-jury.html
date - October 09, 2009
Subscribe to:
Posts (Atom)



